US2012322746A1PendingUtilityA1

Methods, compositions, and kits for the treatment of ophthalmic disorders

48
Assignee: CHAPPELL TODD WPriority: Nov 9, 2005Filed: Aug 29, 2012Published: Dec 20, 2012
Est. expiryNov 9, 2025(expired)· nominal 20-yr term from priority
Inventors:Todd W. ChappellM. NicholsDaniel Grau
A61P 37/02A61P 9/12A61P 37/00A61P 9/14A61P 37/08A61P 9/00A61P 37/06A61P 9/10A61P 7/10A61P 43/00A61P 27/02A61P 27/08A61P 29/00A61P 27/14A61P 27/06A61P 31/00A61P 27/12A61P 25/00A61P 35/00A61P 25/04A61P 31/12A61P 35/02A61P 1/00A61P 21/04A61K 31/4745A61K 31/519A61P 19/02A61K 38/13A61P 1/18A61K 31/553A61K 45/06A61K 31/557A61K 9/0048A61K 9/0051A61P 21/00A61P 17/02A61P 17/06A61P 11/06A61K 31/4015A61K 31/573A61P 1/04A61K 31/4545A61P 17/00A61K 9/0014A61P 19/04A61P 1/02A61K 31/5575A61P 11/00A61K 31/222A61K 31/451Y02A50/30
48
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention features methods, kits, and compositions for the treatment of ophthalmic disorders. The compositions include a corticosteroid in combination with a non-steroidal immunophilin-dependent immunosuppressant.

Claims

exact text as granted — not AI-modified
1 . A method of treating an ophthalmic disorder in a patient, said method comprising ophthalmically administering prednisolone or prednisolone acetate and cyclosporine A, wherein said disorder is selected from the group consisting of allergic conjunctivitis and dry eye. 
     
     
         2 . The method of  claim 1  wherein prednisolone or prednisolone acetate is administered at a concentration of 0.12% and said cyclosporine A is administered at a concentration of 0.01% or 0.02%. 
     
     
         3 . The method of  claim 2 , wherein said ophthalmic disorder is dry eye. 
     
     
         4 . The method of  claim 2 , wherein said ophthalmic disorder is allergic conjunctivitis. 
     
     
         5 . The method of  claim 1 , wherein said cyclosporine A is administered at a concentration of 0.01%. 
     
     
         6 . The method of  claim 1 , wherein said cyclosporine A is administered at a concentration of 0.02%. 
     
     
         7 . The method of  claim 1 , wherein said prednisolone or prednisolone acetate and said cyclosporine A are administered as a single composition. 
     
     
         8 . The method of  claim 7 , wherein said composition is a solution, gel, ointment, suspension, emulsion, or solid insert. 
     
     
         9 . The method of  claim 7 , wherein said prednisolone or prednisolone acetate and said cyclosporine A are the sole active ingredients of said composition.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.